CTAs are almost max long in equities, have very limited room to buy: UBS
Investing.com - RBC Capital raised its price target on Bicycle Therapeutics (NASDAQ:BCYC) to $27.00 from $25.00 on Monday, while maintaining an Outperform rating on the stock. The company, currently trading at $7.47 and showing a 67% decline over the past year, appears undervalued according to InvestingPro analysis.
The price target increase follows Bicycle Therapeutics’ second-quarter 2025 earnings report and subsequent management discussions with the research firm.
RBC Capital noted that the Duravelo-2 dose selection update remains on track for the fourth quarter of 2025, with additional updates on Duravelo-1 now expected in 2026 rather than earlier.
The research firm highlighted Bicycle’s restructuring efforts, which aim to extend the company’s cash runway into 2028 while preserving most key programs.
RBC Capital expressed confidence that Bicycle’s zelenectide could deliver competitive efficacy compared to Padcev with an improved safety profile, suggesting the $2 billion oncology opportunity for this asset is currently undervalued by the market. With analyst price targets ranging from $13 to $48, investors can access detailed financial analysis and 8 additional key insights through InvestingPro’s comprehensive research report.
In other recent news, RadioMedix has been recognized by Cantor Fitzgerald for its substantial contributions to the radiopharmaceutical industry. The Texas-based company has been a pioneer in this field for over twenty years, operating one of the largest radiopharmaceutical manufacturing facilities in the United States. RadioMedix’s expertise is further highlighted by its successful out-licensing of two assets, which were later acquired by major pharmaceutical companies Sanofi (NASDAQ:SNY) and AstraZeneca (NASDAQ:AZN). Cantor Fitzgerald analysts discussed the company’s evolution and business model, which includes manufacturing, diagnostics, and therapeutics. The analysis also touched on the comparative efficacy of lead-212 and actinium-225 as alpha particles in medical applications, underscoring RadioMedix’s innovative approach in the sector. These recent developments position RadioMedix as a significant player in the radiopharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.